Literature DB >> 15682357

Lessons to be learned from the Vioxx debacle.

George A Beller.   

Abstract

Mesh:

Substances:

Year:  2005        PMID: 15682357     DOI: 10.1016/j.nuclcard.2004.11.007

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  6 in total

1.  Failing the public health--rofecoxib, Merck, and the FDA.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

2.  Vioxx, the implosion of Merck, and aftershocks at the FDA.

Authors:  Richard Horton
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321

Review 3.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

4.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors:  Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal:  Lancet       Date:  2004 Dec 4-10       Impact factor: 79.321

5.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

6.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.